UNFPA is pleased to invite Manufacturers of Reproductive Health Medicines to submit an Expression of Interest (EOI) for product evaluation by WHO Expert Review Panel (ERP) regarding RH medicines.
 
Products of interest including new categories: 

1. Injectable hormonal contraceptives

• medroxyprogesterone acetate, depot injection 150 mg/ml, in 1-ml vial
• medroxyprogesterone acetate + estradiol cypionate, injection 25 mg + 5 mg
• norethisterone enanthate, injection 200 mg
• norethisterone enanthate + estradiol valerate, injection 50 mg + 5 mg
• depot medroxyprogesterone acetate (DMPA-SC),
• subcutaneously administered injection 104 mg/0.65 mL

2. Implantable contraceptives

• Levonorgestrel, two-rod hormone releasing implant, each rod containing 75 mg (150 mg in total)
• Etonogestrel, implant, 68 mg of etonogestrel

3. Hormonal intra-uterine device - new

• Levonorgestrel intra-uterine system (Intrauterine system with reservoir containing 52 mg of levonorgestrel)

4. Intravaginal contraceptives - new

• Progesterone vaginal ring (Progesterone‐releasing vaginal ring containing 2.074 g of micronized progesterone)

5. Utero-tonics - new 

• oxytocin, injection 10 IU, 1-ml (IM/IV)
• mifepristone 200 mg tablet (only to be used in combination with misoprostol)
• mifepristone 200 mg tablet co-packaged with 4 tablets of misoprostol 200 microgram¹
• heat-stable carbetocin, injection 100 microgram/ml – in 1 ml ampoule

6. Treatment of maternal syphilis and prevention of congenital syphilis     

• Adult formulation -
  • Benzathine benzylpenicillin 2.4 million units per dose in vial for reconstitution and intramuscular injection

Deadline:  All submissions must reach the UNFPA in Copenhagen by Thursday, 17 June 2019, at 17.00h CEST.

Please click on the UNGM link below for more information:

https://www.ungm.org/Public/Notice/89003